Table 4.

Doxorubicin and Cyclophosphamide, Then Paclitaxel and Trastuzumab Compared With Doxorubicin and Cyclophosphamide, Then Paclitaxel: Hazard of Death and Hazard of Disease Event Within Subgroups

Factor	No. of Patients	OS		DFS
		HR	95% CI	HR	95% CI
Age, years
< 40	654	0.67	0.46 to 0.99	0.50	0.37 to 0.67
40-49	1,373	0.65	0.49 to 0.86	0.64	0.51 to 0.78
50-59	1,336	0.68	0.52 to 0.90	0.64	0.52 to 0.79
≥ 60	683	0.51	0.37 to 0.69	0.63	0.49 to 0.82
Hormone receptor status
ER-negative and PgR-negative	1,828	0.65	0.53 to 0.80	0.62	0.52 to 0.73
ER-positive or PgR-positive	2,215	0.61	0.49 to 0.76	0.61	0.51 to 0.72
Tumor size, cm
0.1-2	1,598	0.51	0.38 to 0.69	0.55	0.44 to 0.68
2.1-5.0	2,096	0.68	0.56 to 0.82	0.65	0.56 to 0.76
≥ 5.1	345	0.58	0.39 to 0.88	0.47	0.33 to 0.67

Abbreviations: DFS, disease-free survival; ER, estrogen receptor; HR, hazard ratio; OS, overall survival; PgR, progesterone receptor.